Skip to main content
. 2020 Apr 14;40(4):181–193. doi: 10.1002/cac2.12024

FIGURE 3.

FIGURE 3

Kaplan–Meier estimates of invasive disease‐free survival for patients in the low recurrence risk group and high recurrence group according to Surexam® 21‐gene RS and TAILORx clinical trial criteria. a all patients; b patients older than 50 years of age; c patients 50 years of age or younger.

Abbreviations: RS recurrence score